We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
94 hedge funds and large institutions have $13M invested in Galectin Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
192% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 12
19% more funds holding
Funds holding: 79 → 94 (+15)
0.55% more ownership
Funds ownership: 15.65% → 16.2% (+0.55%)
23% less call options, than puts
Call options by funds: $5.86M | Put options by funds: $7.59M
52% less capital invested
Capital invested by funds: $26.8M → $13M (-$13.8M)
Holders
94
Holders Change
+15
Holders Change %
+18.99%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
35
Reduced
12
Closed
6
Calls
$5.86M
Puts
$7.59M
Net Calls
-$1.74M
Net Calls Change
-$171K
Top Buyers
| 1 |
RGF
Retirement Guys Formula
Maumee,
Ohio
|
+$219K |
| 2 |
LPL Financial
San Diego,
California
|
+$137K |
| 3 |
BlackRock
New York
|
+$107K |
| 4 |
Morgan Stanley
New York
|
+$105K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$89.7K |
